Clinical Trial Detail

NCT ID NCT02323191
Title A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Hoffmann-La Roche

stomach cancer

urinary bladder cancer

Her2-receptor negative breast cancer

ovarian cancer



Atezolizumab + Emactuzumab

Age Groups: adult senior

Additional content available in CKB BOOST